# Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma

> **NCT01781468** · PHASE3 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 328 (actual)

## Conditions studied

- Fatigue

## Interventions

- **DRUG:** armodafinil 150 mg
- **OTHER:** Placebo
- **DRUG:** armodafinil 250 mg

## Key facts

- **NCT ID:** NCT01781468
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-21
- **Primary completion:** 2019-05
- **Final completion:** 2019-12-15
- **Target enrollment:** 328 (ACTUAL)
- **Last updated:** 2025-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01781468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01781468, "Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01781468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*